glp 1 agonisti Glucagon-like peptide-1 A schematic overview of GLP-1

Whoosh combines oral delivery options, a physician-guided microdosing philosophy, and a streamlined telehealth experience designed for health-conscious adults who want results without the friction

To view or add a comment, sign in Considering a career in mental health

Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development

Works as advertised

And I went down a rabbit hole

Im not the person who does product reviews or evangelizes about anything until this journey, and Im so grateful for going through this as a Ro member